Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta-analysis.
meta‐analysis
randomized clinical trials
renal replacement therapy
sevelamer carbonate
sucroferric oxyhydroxide
Journal
Hemodialysis international. International Symposium on Home Hemodialysis
ISSN: 1542-4758
Titre abrégé: Hemodial Int
Pays: Canada
ID NLM: 101093910
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
revised:
24
09
2024
received:
30
05
2024
accepted:
05
10
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
aheadofprint
Résumé
Phosphate binders are commonly used in patients receiving kidney replacement therapy (KRT), aiming to reduce and maintain serum phosphorus. Chronic kidney disease-mineral and bone disorder has been linked to reduced lifespan and worsened quality of life. This study aims to examine the efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate in patients receiving KRT. The data sources examined were MEDLINE (PubMed), Scopus, and the Cochrane Central Register of Controlled Clinical Trials with a search deadline of October 2023. We examined randomized controlled trials that compared sucroferric oxyhydroxide versus sevelamer carbonate in the adult population receiving KRT. We performed a meta-analysis combining the data from trials, using R-studio. Inclusion criteria were met by five randomized trials. There was no statistically significant difference in the reduction of serum phosphorus between the two groups (MD: -0.07 mmol/L, 95% CI-random effects: -0.15 to 0.02). In the same line, a non-statistically significant difference was observed in serum i-PTH reduction between the two drugs (MD = -1.53 mg/dL, 95% CI = (-4.45, 1.4), p = 0.26, random effects model). No statistically significant difference was observed in all adverse events between the two groups (odds ratio: 1.11, 95% CI: 0.65-1.88, random effects model). Further analysis of gastrointestinal adverse events revealed that sevelamer carbonate increases gastrointestinal adverse events by up to 60% (odds ratio: 1.60, 95% CI: 1.31-1.97, common (fixed) effect model). This meta-analysis of randomized trials showed that both drugs, sucroferric oxyhydroxide and sevelamer equally and effectively controlled serum phosphorus levels, whereas sucroferric oxyhydroxide revealed a better profile in terms of gastrointestinal adverse events. Sucroferric oxyhydroxide is a valuable option for patients receiving KRT when sevelamer carbonate is more difficult to tolerate.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Hemodialysis International published by Wiley Periodicals LLC on behalf of International Society for Hemodialysis.
Références
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al. Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD). Cochrane Database Syst Rev. 2018;8(8):CD006023. https://doi.org/10.1002/14651858.CD006023.pub3
Berner T, Ferro C, Dieguez G, Metz S, Moore J, Szabo E, et al. Real‐world phosphate binder use among dialysis‐dependent patients with CKD. Nephron. 2023;147(10):583–590. https://doi.org/10.1159/000530230
Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Gutiérrez OM, Jimenez EY, et al. State‐of‐the‐art management of hyperphosphatemia in patients with CKD: an NKF‐KDOQI controversies perspective. Am J Kidney Dis. 2021;77(1):132–141. https://doi.org/10.1053/j.ajkd.2020.05.025
Bousher A, Al‐Makki A, Sutton J, Shepler B. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis. Clin Ther. 2014;36(12):2082–2093. https://doi.org/10.1016/j.clinthera.2014.09.021
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142. https://doi.org/10.1002/14651858.ED000142
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta‐analysis with R: a practical tutorial. Evid Based Mental Health. 2019;22(4):153–160. https://doi.org/10.1136/ebmental-2019-300117
Jackson D, Law M, Rücker G, Schwarzer G. The Hartung‐Knapp modification for random‐effects meta‐analysis: a useful refinement but are there any residual concerns? Stat Med. 2017;36(25):3923–3934. https://doi.org/10.1002/sim.7411
Huedo‐Medina TB, Sánchez‐Meca J, Marín‐Martínez F, Botella J. Assessing heterogeneity in meta‐analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206. https://doi.org/10.1037/1082-989X.11.2.193
Luchini C, Veronese N, Nottegar A, Shin JI, Gentile G, Granziol U, et al. Assessing the quality of studies in meta‐research: review/guidelines on the most important quality assessment tools. Pharm Stat. 2021;20(1):185–195. https://doi.org/10.1002/pst.2068
Floege J, Covic AC, Ketteler M, Mann JFE, Rastogi A, Spinowitz B, et al. Long‐term effects of the iron‐based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dialysis Transplant. 2015;30(6):1037–1046. https://doi.org/10.1093/ndt/gfv006
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. A phase III study of the efficacy and safety of a novel iron‐based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638–647. https://doi.org/10.1038/ki.2014.58
Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open‐label, multicentre, 12‐week phase III study. Nephrol Ther. 2017;22(4):293–300. https://doi.org/10.1111/nep.12891
Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron‐based phosphate binder PA21 in hemodialysis patients. CJASN. 2013;8(2):280–289. https://doi.org/10.2215/CJN.08230811
Liu J, Zuo L, Walpen S, Bernard L, Marty M, Enoiu M. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer carbonate in Chinese dialysis patients with Hyperphosphataemia: a randomised, open‐label, multicentre, 12‐week phase III study. Nephron. 2023;148:22–33. https://doi.org/10.1159/000531869
Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, et al. Phosphate‐binding agents in adults with CKD: a network meta‐analysis of randomized trials. Am J Kidney Dis. 2016;68(5):691–702. https://doi.org/10.1053/j.ajkd.2016.05.015
Xie D, Ye N, Li M. A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients. Int Urol Nephrol. 2018;50(5):905–909. https://doi.org/10.1007/s11255-017-1774-9
Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium‐based versus non‐calcium‐based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta‐analysis. Lancet. 2013;382(9900):1268–1277. https://doi.org/10.1016/S0140-6736(13)60897-1
Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium‐based binders for treatment of hyperphosphatemia in CKD: a meta‐analysis of randomized controlled trials. Clin J Am Soc Nephrol. 2016;11(2):232–244.
Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open‐label 24‐month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771–778. https://doi.org/10.1053/j.ajkd.2013.03.023
Luo L, Chen Q. Effect of CKD–MBD phenotype on health‐related quality of life in patients receiving maintenance hemodialysis: a cross‐sectional study. J Int Med Res. 2020;48(2):30006051989584. https://doi.org/10.1177/0300060519895844
Bataille P, Delattre V, Daroux M. Oxyhydroxyde sucroferrique, un nouveau chélateur des phosphates à base de fer. Quelle utilisation chez le patient dialysé? Nephrol Ther. 2017;13:S103–S108. https://doi.org/10.1016/j.nephro.2017.01.004
Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438–441. https://doi.org/10.1038/sj.ki.5002059
Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, et al. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renovasc Dis. 2016;9:11–19. https://doi.org/10.2147/IJNRD.S78040
Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, et al. Iron‐related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2017;32(8):1330–1338. https://doi.org/10.1093/ndt/gfw242
Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, et al. Characteristics of patients who achieve serum phosphorus control on sucroferric oxyhydroxide or sevelamer carbonate: a post hoc analysis of a phase 3 study. Nephron. 2020;144(9):428–439. https://doi.org/10.1159/000507258
Coyne DW, Sprague SM, Vervloet M, Ramos R, Kalantar‐Zadeh K. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real‐world evidence. J Nephrol. 2022;35(3):875–888. https://doi.org/10.1007/s40620-021-01241-5
Ferreira A, Pinto B, Navarro D, Aniceto J, Neves PL, Ponce P. Effectiveness of sucroferric oxyhydroxide in patients on on‐line hemodiafiltration in real‐world clinical practice: a retrospective study. J Bras Nefrol. 2019;41(2):224–230. https://doi.org/10.1590/2175-8239-jbn-2018-0142
Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol. 2016;29(3):329–340. https://doi.org/10.1007/s40620-016-0266-9
Floege J. Phosphate binders in chronic kidney disease: an updated narrative review of recent data. J Nephrol. 2020;33(3):497–508. https://doi.org/10.1007/s40620-019-00689-w
Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, et al. One‐year efficacy and safety of the iron‐based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dialysis Transplant. 2017;32(11):1918–1926. https://doi.org/10.1093/ndt/gfw460
Floege J, Sprague S, Rastogi A, Ketteler M, Covic A, Rakov V, et al. Mp381 characteristics of responders and non‐responders to treatment with sucroferric oxyhydroxide: a post hoc analysis of a phase 3 study. Nephrol Dialysis Transplant. 2016;31(suppl_1):i466. https://doi.org/10.1093/ndt/gfw190.38
Greig SL, Plosker GL. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis. Drugs. 2015;75(5):533–542. https://doi.org/10.1007/s40265-015-0366-1
Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD‐MBD) guideline update: what's changed and why it matters. Kidney Int. 2017;92(1):26–36. https://doi.org/10.1016/j.kint.2017.04.006
Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, et al. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients. Nephrol Dialysis Transplant. 2019;34(7):1163–1170. https://doi.org/10.1093/ndt/gfy127
Koiwa F, Yokoyama K, Fukagawa M, Akizawa T. Efficacy and safety of sucroferric oxyhydroxide and calcium carbonate in hemodialysis patients. Kidney Int Rep. 2018;3(1):185–192. https://doi.org/10.1016/j.ekir.2017.10.003
Lioufas NM, Pascoe EM, Hawley CM, Elder GJ, Badve SV, Block GA, et al. Systematic review and meta‐analyses of the effects of phosphate‐lowering agents in nondialysis CKD. JASN. 2022;33(1):59–76. https://doi.org/10.1681/ASN.2021040554
McCullough PA. Phosphate control: the next frontier in dialysis cardiovascular mortality. Cardiorenal Med. 2021;11(3):123–132. https://doi.org/10.1159/000516286
Molony DA, Parameswaran V, Ficociello LH, Mullon C, Kossmann RJ. Sucroferric oxyhydroxide as part of combination phosphate binder therapy among hemodialysis patients. Kidney360. 2020;1(4):263–272. https://doi.org/10.34067/KID.0000332019
Perry CM, Plosker GL. Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease. Drugs. 2014;74(7):771–792. https://doi.org/10.1007/s40265-014-0215-7
Sprague SM, Covic AC, Floege J, Ketteler M, Botha J, Chong EM, et al. Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients. Am J Nephrol. 2016;44(2):104–112. https://doi.org/10.1159/000447600
Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, et al. Long‐term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018;22(4):480–491. https://doi.org/10.1111/hdi.12663